ArticleFrontiers in oncology2026
Artificial intelligence improves risk stratification for breast cancer recurrence and mortality in women exposed to pesticides: a call for reassessment of stratification criteria.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Precision in clinical practice is essential for optimizing patient outcomes and quality of life. To enhance diagnostic accuracy and treatment efficacy, various healthcare studies - including those on breast cancer - have increasingly adopted machine learning (ML) techniques. By leveraging ML to analyze patient history data, researchers can predict disease outcomes more accurately and tailor treatments effectively. Brazil, the world's largest consumer of pesticides, faces significant public health challenges due to occupational exposure. Notably, pesticide exposure is not considered a risk factor in the current Diagnostic and Therapeutic Guidelines for Breast Carcinoma (Joint Ordinance No. 5, of April 18, 2019), which guides the diagnosis, treatment, and monitoring of breast cancer patients. In a recent study published by our group, we observed hidden risks associated with occupational pesticide exposure in women with breast cancer. The correlation between pesticide exposure and the severity of breast cancer in female farmers has already been demonstrated by our group previously. In this study, we focus on predicting the risk of death and cancer recurrence in these patients, comparing this population with patients diagnosed with cancer but not exposed to pesticides. Methods: In this context, the present study employed ML algorithms to predict the risk stratification for recurrence and mortality in breast cancer patients and to re-stratify them by incorporating pesticide exposure as an additional risk factor. Clinicopathological data from 427 women were used to train logistic regression, random forest, support vector machine, and gradient boosting, obtaining models to identify the algorithm with superior predictive performance. These models were applied to patient stratification, with pesticide exposure included as an additional parameter. Model performance was evaluated using precision, accuracy, recall, F1-score, and the area under the ROC curve (AUC-ROC). Results and discussion: Incorporating pesticide exposure data resulted in a 24.12% improvement in the prediction quality of the best model (random forest), demonstrating that ML models can better learn and understand patterns in the dataset when this risk factor is considered. These findings underscore the necessity of including pesticide exposure in risk stratification, particularly in regions of family farming.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.